3,632
edits
No edit summary |
No edit summary |
||
Line 1: | Line 1: | ||
{{Stub Notice}} | {{Stub Notice}} | ||
[https://pubmed.ncbi.nlm.nih.gov/36520073/ 2023 American Society of Anesthesiologists Practice Guidelines for Monitoring and Antagonism of Neuromuscular Blockade: A Report by the American Society of Anesthesiologists Task Force on Neuromuscular Blockade. Anesthesiology 2023;138:13-41] | |||
[https://pubmed.ncbi.nlm.nih.gov/31584918/ Retrospective Analysis of the Safety and Efficacy of Sugammadex Versus Neostigmine for the Reversal of Neuromuscular Blockade in Children] | [https://pubmed.ncbi.nlm.nih.gov/31584918/ Retrospective Analysis of the Safety and Efficacy of Sugammadex Versus Neostigmine for the Reversal of Neuromuscular Blockade in Children] | ||
Line 15: | Line 17: | ||
[https://www.bjanaesthesia.org/article/S0007-0912(19)30835-9/fulltext Comparison of incidence of anaphylaxis between sugammadex and neostigmine: a retrospective multicentre observational study] | [https://www.bjanaesthesia.org/article/S0007-0912(19)30835-9/fulltext Comparison of incidence of anaphylaxis between sugammadex and neostigmine: a retrospective multicentre observational study] | ||
[https://pubmed.ncbi.nlm.nih.gov/33543867/ A Survey of the Society for Pediatric Anesthesia on the Use, Monitoring, and Antagonism of Neuromuscular Blockade] | |||
[https://pubmed.ncbi.nlm.nih.gov/28806470/ Efficacy and safety of sugammadex versus neostigmine in reversing neuromuscular blockade in adults] | |||
[https://pubmed.ncbi.nlm.nih.gov/29280475/ The comparative efficacy and safety of sugammadex and neostigmine in reversing neuromuscular blockade in adults. A Cochrane systematic review with meta-analysis and trial sequential analysis] | |||
[https://pubmed.ncbi.nlm.nih.gov/30594097/ Incidence, risk factors, and consequences of residual neuromuscular block in the United States: The prospective, observational, multicenter RECITE-US study] | |||
[https://pubmed.ncbi.nlm.nih.gov/26646837/ Sugammadex and rocuronium-induced anaphylaxis] | [https://pubmed.ncbi.nlm.nih.gov/26646837/ Sugammadex and rocuronium-induced anaphylaxis] | ||
Line 33: | Line 35: | ||
[https://pubmed.ncbi.nlm.nih.gov/10638896/ Neuromuscular effects of mivacurium in 2- to 12-yr-old children with burn injury] | [https://pubmed.ncbi.nlm.nih.gov/10638896/ Neuromuscular effects of mivacurium in 2- to 12-yr-old children with burn injury] | ||
[https://pubmed.ncbi.nlm.nih.gov/33543867/ A Survey of the Society for Pediatric Anesthesia on the Use, Monitoring, and Antagonism of Neuromuscular Blockade] | |||
[https://pubmed.ncbi.nlm.nih.gov/36520074/ Measuring Success of Patient Safety Initiatives: The 2023 American Society of Anesthesiologists Practice Guidelines for Monitoring and Antagonism of Neuromuscular Blockade] | |||
[https://pubmed.ncbi.nlm.nih.gov/34813652/ Quantitative Neuromuscular Monitoring and Postoperative Outcomes: A Narrative Review] | |||
[https://pubmed.ncbi.nlm.nih.gov/28795964/ Neuromuscular Monitoring in the Perioperative Period] | |||
[https://pubmed.ncbi.nlm.nih.gov/31607388/ Use of a train-of-four ratio of 0.95 versus 0.9 for tracheal extubation: an exploratory analysis of POPULAR data] | |||
[https://pubmed.ncbi.nlm.nih.gov/23001053/ Intraoperative neuromuscular monitoring site and residual paralysis] | |||
[https://pubmed.ncbi.nlm.nih.gov/35188958/ Quantitative Neuromuscular Monitoring in Clinical Practice: A Professional Practice Change Initiative] |